COVID-19 ACTIV 2d CLINICAL TRIAL AT IHHN TO BE INITIATED

Indus Hospital & Health Network (IHHN) is initiating another COVID-19 drug trial – ACTIV-2d Clinical Drug, for individuals testing positive for this virus.

ACTIV-2d is a Shionogi & Co. Ltd (Japan) sponsored study based on international ethical guidelines with a focus on patient safety. It aims to evaluate the effectiveness and safety of a novel investigational oral antiviral therapy called S-217622 in adults with early COVID-19 symptoms.

Potential participants will undergo screening for COVID-19 via the antibody test or go through a PCR swab to check if they are infected. They must be over 18 years of age, have no major or uncontrolled health issues, and not pregnant, lactating, or planning to conceive until 6 months, to become part of the trial.

Once eligible participants consent to become part of the trial, they will be enrolled and given three tablets on day one and one tablet daily for a further four days. This may be the anti-viral drug or a placebo, which neither the participant nor the trial staff will know as per the trial protocol.

The participant will remain part of the trial for 6 months. During this period, participants will be asked to fill out an electronic diary and keep a record of any reactions after each tablet. Participants will be compensated for their time and travel.

There are over 250 Activ-2D trial sites worldwide. IQVIA is managing sites in Pakistan and The Indus Hospital, Korangi, Karachi site has recently initiated this trial. Information collected via the trial will help researchers in advancing medical knowledge and potentially develop effective and affordable treatment options for mild to moderate COVID-19 in Pakistan.

To find out if you or someone you know is eligible for this trial and to get more information, please contact +923332867476.